Skip to main content

Table 1 Baseline characteristics

From: High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial

 

Vitamin D group (N = 35)

Placebo group (N = 33)

Females

N (%)

24 (69)

24 (73)

Age (years)

Mean (range)

40 (21–50)

41 (26–50)

Body mass index

Mean (range)

25.9 (21.0–40.7)

26.4 (18.4–39.9)

Ongoing smoking

N (%)

15 (43)

14 (42)

EDSS

Median (range)

2.5 (0–4.5)

2.0 (0–4.5)

Annualised relapse rate

Mean (range)

0.11 (0–0.54)

0.15 (0–1.10)

Immunomodulatory treatment

N (%)

17 (49)a

17 (52)b

Serum 25(OH)D (nmol/L)

Mean (SD)

55.6 (29.0)

57.3 (21.8)

Hip BMD (mg/cm2)

Mean (SD)

1018.8 (98.8)

968.9 (119.9)

Spine BMD (mg/cm2)

Mean (SD)

1205.2 (117.7)

1165.7 (135.6)

Distal radius BMD (mg/cm2)

Mean (SD)

484.8 (67.1)

472.8 (80.6)

  1. a16 patients on IFN-β and one on glatiramer acetate
  2. b15 patients on IFN-β, one on glatiramer acetate and one on natalizumab